Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China.

Ther Adv Gastroenterol · 2025 · PMC12618851 · PMID 41245387

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

However, the effect size diminished after multivariate adjustment and did not reach statistical significance (aOR = 1.72, 95% CI: 0.96–3.08, p = 0.07), indicating that its efficacy may be partially mediated by confounding factors, although its potential clinical relevance remains noteworthy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for &lt;i&gt;Helicobacter pylori&lt;/i&gt; eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China.

The sentences

Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China.